Lack of consensus on optimal uterotonic protocols for **Postpartum Hemorrhage** prevention during C-section persists despite high maternal mortality
Background
Postpartum hemorrhage (PPH) is a major cause of maternal mortality, accounting for about 27% of maternal deaths globally. It is defined as blood loss exceeding 1000 ml after a C-section. The primary physiological driver of PPH is uterine atony, which is responsible for 70% of all PPH cases. While various uterotonics such as oxytocin, misoprostol, ergometrine, and carbetocin are available and used, there is currently no widespread agreement on which medication or combination constitutes the most effective protocol for PPH prevention, especially in high-risk groups undergoing C-sections. This lack of consensus highlights a critical gap in standardized maternal care.
Why It Matters
Establishing clear, evidence-based protocols for PPH prevention is critical for reducing maternal mortality and morbidity. The current lack of consensus on the most effective uterotonic regimen means healthcare providers must often rely on varied institutional guidelines or individual clinical judgment, which can lead to inconsistencies in care, particularly for high-risk patients undergoing C-sections. This situation underscores an urgent need for rigorous comparative studies to identify optimal dosing, timing, and combinations of uterotonics. For clinicians, this emphasizes the importance of meticulous risk assessment and a thorough understanding of all available uterotonic options, while also highlighting the ongoing necessity for research to develop universally accepted, highly effective preventative strategies.
postpartum hemorrhage
maternal mortality
uterine atony
c-section
uterotonics
obstetrics